Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma

Trial Profile

Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 02 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top